Monalizumab is a humanized monoclonal antibody targeting NKG2A, with a mechanism of action that specifically blocks the interaction between NKG2A on NK cell surfaces and HLA-E molecules highly expressed on tumor cells, thereby activating antitumor immune responses mediated by NK cells and cytotoxic T lymphocytes (CTLs). This evidence concerns the gene KLRC1 and neoplasm.